Neurofilament light chain as a biomarker for monitoring response to change in treatment in hereditary ATTR amyloidosis

Amyloid. 2023 Sep;30(3):351-352. doi: 10.1080/13506129.2023.2187678. Epub 2023 Mar 12.

Authors

Mitsuto Sato¹, Yusuke Mochizuki¹, Yusuke Takahashi¹, Ken Takasone¹, Emre Aldinc², Simina Ticau², Gang Jia², Yoshiki Sekijima^{1

3}

Affiliations

¹ Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Nagano, Japan.
² Alnylam Pharmaceuticals, Cambridge, MA, USA.
³ Institute for Biomedical Sciences, Shinshu University, Nagano, Japan.

PMID: 36908191
DOI: 10.1080/13506129.2023.2187678

No abstract available

MeSH terms

Amyloid Neuropathies, Familial* / diagnosis
Amyloid Neuropathies, Familial* / drug therapy
Amyloid Neuropathies, Familial* / genetics
Amyloidosis, Familial*
Biomarkers
Humans
Intermediate Filaments
Prealbumin / genetics

Substances

Biomarkers
Prealbumin